ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors

Key combination for the treatment of Small Cell Lung CancerMADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, the patent is expected to remain in force until at leas ...